Allogeneic UCB Therapy With EPO in Children With CP

Exclusion Criteria

• •Current aspiration pneumonia
• •Known genetic disease
• •History of hypersensitivity reaction to any study drugs pertinent to the study
• •History of participation in any other study with stem cell
• •Prior treatment with EPO within 3 months prior to study entry
• •Known coagulopathy with family history of thrombosis or medical history of recurrent thrombosis
• •Patient with severe seizure disease who has clinical convulsion despite combination therapy with 3 or more agents
• •Uncontrolled hypertension defined as systolic blood pressure \>115 mmHg and/or diastolic blood pressure \>70 mmHg
• •Hepatic impairment defined as asparate aminotransferase (AST) \>55 IU/L and/or alanine aminotransferase (ALT) \>45 IU/L
• •Renal impairment defined as creatinine (Cr) ≥1.2 mg/dL
• •Absolute neutrophil count ≤500/dL
• •Presence of diagnosed or suspected malignant tumor and/or hematologic malignancy
• •Non-compliance with study visits specified in the protocol or unwillingness of care-giver due to lack of understanding of the patient